Arrowhead Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ARWR)

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) released its quarterly earnings results on Monday, August, 5th. The biotechnology company reported $0.21 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.34 by $0.13. The biotechnology company earned $42.70 million during the quarter, compared to analysts' expectations of $59.05 million. Arrowhead Pharmaceuticals had a return on equity of 26.27% and a net margin of 33.28%. View Arrowhead Pharmaceuticals' Earnings History.

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, December 10th 2019. View Earnings Estimates for Arrowhead Pharmaceuticals.

6 equities research analysts have issued twelve-month target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $24.00 to $50.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $36.70 in the next year. This suggests a possible upside of 6.3% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals.

Headlines about ARWR stock have been trending positive this week, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Arrowhead Pharmaceuticals.

Some companies that are related to Arrowhead Pharmaceuticals include Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Ionis Pharmaceuticals (IONS), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT) and Jazz Pharmaceuticals (JAZZ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), Sasol (SSL), Sarepta Therapeutics (SRPT), Biogen (BIIB), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Omeros (OMER), Exelixis (EXEL) and Alliance Resource Partners (ARLP).

Arrowhead Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.08%), Pacer Advisors Inc. (0.02%), CIBC Private Wealth Group LLC (0.01%) and Arden Trust Co (0.01%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

ARWR stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

ARWR stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Pacer Advisors Inc. and Arden Trust Co. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARWR stock can currently be purchased for approximately $34.51.

Arrowhead Pharmaceuticals has a market capitalization of $3.27 billion and generates $16.14 million in revenue each year. The biotechnology company earns $-54,450,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.View Additional Information About Arrowhead Pharmaceuticals.

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]